WuXi AppTec
Business Services · China · 36,997 Employees
Established in December 2000, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients.Read More
View Company Info for Free
Who is WuXi AppTec
Headquarters
Phone Number
Website
Revenue
Industry
WuXi AppTec Org Chart
WuXi AppTec Email Formats
WuXi AppTec uses at least 5 email formats with first_last (ex. John_Smith@wuxiapptec.com) being used 46.1% of the time
WuXi AppTec Email Formats | Percentage | |
---|---|---|
first_last | John_Smith@wuxiapptec.com | 46.1% |
first.last | John.Smith@wuxiapptec.com | 35.3% |
last_first | Smith_John@wuxiapptec.com | 6.9% |
first_last | John_Smith@wuxibiologics.com | 0.4% |
first.last | John.Smith@wuxibiologics.com | 0.4% |
Get Verified Emails
WuXi AppTec Company Metrics
$1.7B
Total Funding Amount
$1.5B
Most Recent Funding Amount
2
Number of Funding Rounds
Jul 18, 2022
WuXi Clinical
Feb 17, 2018
CMAB BioPharma
Apr 22, 2012
ResourcingPoint
AppTec Laboratory Services
Xenobiotics Laboratory
See More Acquisitions & Subsidiaries
WuXi AppTec Tech Stack
WuXi AppTec News & Media
Global Small Molecule CMO Market Size and Forecast | Lonza Group, Wuxi AppTec Co. Ltd ...
New Jersey, United States - The Global Small Molecule CMO Market Report is a comprehensive and informative analysis of the industry, designed toWuXi AppTec Announced Strong Results of the Second Quarter and First Half of 2023, on Top of an Exceptionally Strong Year in 2022
Revenue of RMB9,908 Million in the Second Quarter, Up 6.7% Year-over-Year; Excluding COVID-19 Commercial Projects, Up 39.5% Revenue of RMB18,871 Million in the First Half, Up 6.3% Year-over-Year; Excluding COVID-19 Commercial Projects, Up 27.9% Net Profit Attributable to Owners of the...WuXi AppTec Announced Strong Results of the Second Quarter and First Half of 2023, on Top of an Exceptionally Strong Year in 2022
Revenue of RMB9,908 Million in the Second Quarter, Up 6.7% Year-over-Year; Excluding COVID-19 Commercial Projects, Up 39.5% Revenue of RMB18,871 Million in the First Half, Up 6.3% Year-over-Year; Excluding COVID-19 Commercial Projects, Up 27.9% Net Profit Attributable to Owners of the Company for the First Half Increased 14.6% to RMB 5,313 Million Diluted Earnings per Share (EPS) for the First Half Increased 20.9% to RMB1.79 Adjusted Non-IFRS Net Profit Attributable to Owners of the CompanyGlobal Small Molecule CMO Market Size and Forecast | Lonza Group, Wuxi AppTec Co. Ltd ...
New Jersey, United States - The Global Small Molecule CMO market is projected to experience significant growth, as per the latest research report
Frequently Asked Questions regarding WuXi AppTec
Established in December 2000, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients.... Read More